**Gender-related differences in systemic sclerosis**

Michael Hughes1,2, John D Pauling3,4, Laura Armstrong-James5, Christopher P Denton6, Paul Galdas7, Caroline Flurey8

Author affiliations

1. Department of Rheumatology, Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
2. Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, The University of Manchester, UK.
3. Royal National Hospital for Rheumatic Diseases (at Royal United Hospitals), Bath, UK.
4. Department of Pharmacy and Pharmacology, University of Bath, Bath, UK.
5. Equality and Diversity Unit, University of the West of England, Bristol, UK.
6. Centre for Rheumatology, Royal Free Hospital, University College London, London, UK.
7. Department of Health Sciences, University of York, York, UK.
8. Department of Health and Social Sciences, University of the West of England, Bristol, UK.

**Corresponding Author:**

Dr Michael Hughes BSc (Hons) MBBS MSc MRCP (UK) (Rheumatology) PhD

Consultant Rheumatologist

Department of Rheumatology, Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, S10 2JF, UK.

[Michael.hughes-6@postgrad.manchester.ac.uk](mailto:Michael.hughes-6@postgrad.manchester.ac.uk) | Telephone: +44 (0)114 271 1900

**Declaration of interest**

Dr Hughes – None. Dr Pauling has undertaken consultancy work and received speaker honoraria from Actelion pharmaceuticals. Dr Pauling has undertaken consultancy work for Boehringer Ingelheim. Dr Armstrong-James – None. Professor Denton – None. Professor Galdas – None. Dr Flurey – None.

Word count = 3704 | References = 92

**Abstract**

Systemic sclerosis (SSc) is a complex autoimmune connective tissue disease which is characterised by autoimmunity, widespread tissue fibrosis of the skin and internal organs, and vasculopathic alterations. SSc is more common in women but has a more severe expression of disease including internal organ-based complications and higher mortality in men. The extant literature shows that although important pathophysiological sex differences are present in SSc, behavioural differences (e.g. higher smoking rates in men) and occupational exposures may contribute to poorer outcomes in men with SSc. The higher death male death rate in the general population and greater prevalence of lung fibrosis are likely the key factors responsible for excess mortality found in men. Other important factors include (but are not limited to) a greater prevalence of the disease subset, delayed time to diagnosis, and higher disease activity in early disease in men. SSc carries a significant burden of disease-related morbidity; however, no qualitative studies to date have focussed on gender differences in SSc. The purpose of this review is to provide a comprehensive overview of gender differences in SSc including (but not limited to) epidemiology, pathophysiology, clinical expression of disease, mortality, SSc in transgender individuals, and psychosocial aspects of disease.

Key words = Systemic sclerosis; Scleroderma; Gender: Men; Women; Pathogenesis; Epidemiology; Mortality; Organ-involvement; Treatment

**Take-home messages**

* SSc is more common in women compared to men.
* Men with SSc have a more severe disease course including mortality.
* The pathogenesis of SSc may differ significantly between men and women.
* Delay in diagnosis and health behaviours/occupational exposures may be important.
* Little is known about gender differences relating to psychosocial aspects.

**1. Introduction**

Systemic sclerosis (SSc) is a complex autoimmune connective tissue disease which is characterised by autoimmunity, widespread tissue fibrosis of the skin and internal organs, and vasculopathic alterations (1–3). Although significant advancements have been made in understanding pathogenesis and the availability of a number of treatments for many of the organ-based complications, SSc still carries a significant burden of disease-associated morbidity and mortality. In general, men with SSc have significantly reduced survival rates than women and report more severe disease. The purpose of this review is to examine aspects of sex and gender differences in SSc relating to epidemiology, pathogenesis, diagnosis, health behaviours and occupational exposures, clinical expression of disease including early disease and organ-based complications, mortality, SSc in transgender individuals, and psychosocial aspects of disease.

**2. Review strategy**

The breadth of this comprehensive review was not amenable to a formal systematic literature review procedure due to the need to both identify and appraise a broad range of sources including cross-sectional studies, registry analyses, and qualitative research methods. The following standardised search criteria were applied within the National Institutes of Health's National Library of Medicine (PubMed) to facilitate the identification of manuscripts relevant to pathogenesis, epidemiology and clinical features (2356 citations on 26th May 2019):

((gender) OR (sex) OR (men)) AND ((systemic sclerosis) OR (CREST) OR (Scleroderma)) AND ((pathogenesis) OR (assessment) OR (classification) OR (clinical trial) OR (impact) OR (burden) OR (treatment) OR (clinical) OR (management) OR (features) OR (therapy) OR (work) OR (qualitative) OR (experience) OR (social) OR (function) OR (distress) OR (disability) OR (symptoms) OR (pain) OR (distress) OR (social) OR (quality of life))

In parallel, a specific search was performed to identify manuscripts which were relevant to the psychosocial aspects:

((gender) OR (masculinity) OR (masculine) OR (masculinities) OR (masc\*) OR (men’s health) OR (hegemonic)) AND ((systemic sclerosis) OR (scleroderma) OR (SSc) OR (lcSSc) OR (dcSSc)) AND ((Coping) OR (Cope) OR (self-manage\*) OR (self management) OR (impact) OR( depress\*) OR (low mood) OR (emotion) OR (quality of life) OR (QOL) OR (helplessness) OR (wellbeing) OR (adjustment) OR (adaptation) OR (identity) OR (self care) OR (self-care) OR (self belief) OR (self-belief) OR (self efficacy) OR (self-efficacy) OR (support) OR (psych\*)).

The titles and abstracts of journal articles identified from this search strategy formed the main basis of identifying the relevant works. We also performed grey searches of the manuscripts that were cited within these articles. We excluded articles relating to erectile dysfunction as the focus of this review was on gender-related differences in SSc.

**3. Epidemiology of SSc**

SSc is more common in females compared to males; although the exact ratio between the sexes has varied widely in the reported literature. In general, the ratio between female and males SSc patients is considered to be approximately 3:1 and as high as 7-8:1 (4–12). Tamaki et al (13) reported in their study, which included 629 patients that examined applicants for free medical care in Tokyo, that the male: female ratio was as high as 14.5:1. There is also evidence of variation within individual countries. For example, within the United Kingdom, Silman et al (14) reported that the male: female ratio was 3.92:1 in the West Midlands, whereas, Allocock et al (15) found that the ratio was 4.7:1 in the North East of England. In a recent study that used data from the Clinical Practice Research Datalink between 1994 and 2013, of the 1327 incident cases, the crude and adjusted rate ratio between females and males was 4.9 and 4.7, respectively (16).

3.1. Ethnicity

SSc is more common in African-American (compared to Caucasian) patients, who also exhibit a more severe expression of the disease. This is potentially related to the higher prevalence of the diffuse subset of the disease, including a lower prevalence of anticentromere antibodies (17) and greater positivity of the anti-Scl-70 antibody (4,17,18). Mayes et al (17) investigated the epidemiology, including survival, in a large cohort of patients (n=706, 106 black) based on the census of SSc cases during the period of 1989 to 1991 in the Detroit area. The disease was more frequently observed in black women compared to black men with a reported prevalence of 433.5 and 103.9 per million, respectively (17). In a retrospective study of black patients (n=63) with SSc who attended a tertiary hospital in South Africa, the male to female ratio was 4.6:1 (16). The authors further reported that calcinosis more frequently occurred in men, whereas, arthralgia’s/arthritis were more common in women (16). Nitert and Silver (19) examined the patterns of hospital admissions and emergency room visits among patients (n=785) with SSc over 5 years in South Carolina. The authors found that the number of visits/admissions was greater in black compared with white males, and also for older women aged between 50 to 64 years, and >65 years (19).

**4. Pathogenesis**

The preponderance of SSc in females provides the clearest signal for the existence of important sex-related aetiopathogenic drivers in SSc. Putative factors that may account for differences in both prevalence and observed outcomes include the influence of female reproductive hormones, fetal microchimerism, X-linked genetic factors (including skewed inactivation, X-linked non-coding RNA and X-linked nucleotide polymorphisms) and also environmental/occupational exposures (20).

The potential role of sex hormones on the pathogenesis of SSc has also received research attention. A recent systematic literature of the sex hormones and sex hormone-targeting therapies literature concluded that oestrogens (particularly oestradiol) may have important pro-fibrotic but vasculoprotective properties in SSc (21). Apparent differences in clinical phenotype in females presenting before and after the menopause (22,23) also suggests a link between sex hormone levels and clinical phenotype (with lower fibrosis but higher rates of PAH associated with hypo-oestrogenic states (21). These findings have been challenged by recent work suggesting an anti-fibrotic role of oestrogens in pre-clinical models of SSc (24), which is consistent with the more severe clinical phenotype in males (see below). These contrasting findings have important implications for medications such tamoxifen and their potential effects in SSc. Studies examining androgen levels have yielded conflicting results, but high levels of oestradiol in older men are reported to be associated with heart involvement, skin progression, and death (25). Androgens may also be important in SSc pathogenesis and one study has identified higher levels of androgens in post-menopausal female patients with SSc carrying anti-topoisomerase antibodies (26).

The preponderance of women with SSc (and high prevalence of autoimmunity in Klinefelter’s diseases) has also led to interest in X-linked genes (20,27). Methylation of a number of candidate X-chromosome genes may contribute to increased susceptibility to SSc (and discordance in twin studies) (28). Skewed X-chromosomal inactivation also appears to increase susceptibility to SSc and the suppressive capacity of Tregs (29). An IRAK1 haplotype containing the 196Phe functional variant (rs1059702), located on Xq28, has been shown to confer susceptibility to SSc with strong associations with the diffuse subset, the presence of anti-topoisomerase I antibodies, and SSc-ILD (30) . A study of patients with early SSc (<3 years since first non-RP symptom) enrolled onto the EUSTAR registry, suggested men were more likely to carry anti-Scl-70 (54% vs. 7%) compared to females (31) and the genetic contribution to these observations may relate to genes on the X chromosome. The strong signal within the Xq28 region is also related to overexpression of MECP2 gene (related to diffuse cutaneous SSc) in SSc (32). A recent study reported reduced expression levels of IRAK1 messenger RNA (inter-related to MEP2) in peripheral blood mononuclear cells (PBMCs) in SSc patients compared to controls, but also lower in male patients compared to females and appears to be associated with severe skin involvement (33). PBMC expression of miR-146a (which downregulates IRAK1) is also reduced in SSc patients; particularly in males and those with severe skin involvement (33). Other genes such as IL13RA2 have been shown to be associated with SSc in female populations (34). Recent high-resolution global transcriptome analyses has identified a VGLL3-regulated pro-inflammatory network that promotes female-biased autoimmunity, highlighting the value of studying genetic risk separately in females and males(35). Such studies may help to establish genetic signatures (and potential therapeutic targets) that shed light on sex-related differences in aetiopathogenesis and clinical phenotype in SSc. Pregnancy-related microchimerism may be an additional factor resulting in sex-related differences in SSc. It has been reported that female patients who had more children prior to their diagnosis of SSc, were more likely to have limited SSc and pulmonary fibrosis (36). The interval between the birth of the first child and onset of SSc has also been noted to be shorter when the child was female (36).

Several studies have reported that men are more likely to carry anti-Scl-70 or anti-RNA polymerase III antibodies than anticentromere antibodies (31,37–41). One study has found nucleolar antibodies targeting U3-RNP and Th/To are more common in females (in both Caucasian and African-American population) (39). However, men have also been reported to have a higher probability of being antinuclear antibody negative (41,42). A prospective study from the Spanish Systemic Sclerosis Study Group RESCLE (Registro de ESCLErodermia) register which included 1,506 patients with SSc, men were significantly less likely to be antinuclear antibody positive compared to women (85% vs. 93%, respectively) (41).

**5. Time to diagnosis**

Overall, the literature suggests that women tend to experience a longer time to diagnosis compared to men (41) after the onset of Raynaud’s phenomenon (RP) (43,44), and the first non-RP symptom (44). However, in the previously described study from the Spanish Systemic Sclerosis Study Group, men were reported to have a shorter duration from SSc onset to diagnosis (odds ratio of 0.98) (41). In a study from the Scleroderma Canadian Group registry which included 1,129 patients with SSc, the median time to diagnosis was significantly longer for women with diffuse cutaneous SSc compared to men (1.1 vs. 0.8 years, respectively), following the onset of RP (44). Similarly, in another study of 408 patients with dcSSc, the time to diagnosis after the onset for RP was significantly longer in women compared to men (43). This could potentially be explained (in part) by the overrepresentation of the limited subset of the disease in females, which is often characterised by a long duration of RP (potentially even decades). In addition, as described later, there is evidence to suggest that males have more severe vasculopathy, including digital vascular disease, than females.

**6. Health behaviours and occupational exposures**

Smoking has been reported to be more frequent in males with SSc (41,45). For example, the authors of the previously described study from the RESCLE registry reported that smoking was significantly more common in men compared to women (odds ratio of 2.57) (41). Whereas, in a study which included 231 patients of Greek origin with SSc between 1995 and 2011, there was no significant difference observed in smoking between men and women (46). It is likely that there are important cultural influences in relation to smoking prevalence/gender differences. Important occupational exposures have been implicated in the aetiopathogenesis of SSc (47). In a case control study examining occupational exposure to heavy metals in 100 patients with SSc, the authors found a marked association between antimony and platinum in males, and antimony, cadmium, lead, mercury, palladium and zinc in females (48).

**7. Disease expression**

**7.1. Early SSc**

In the previously described cross-sectional study of EUSTAR patients, in early disease (<3 years from first non-Raynaud’s symptom), men had more active disease (as assessed by the European Scleroderma Study Group SSc activity score), diffuse disease, anti-Scl-70 antibody positivity, elevated acute phase reactants, and pulmonary and muscular involvement (31). These differences between the sexes were confirmed in patients with the limited, but not diffuse subset of the disease (31). Furthermore, these findings were also similar when patients (n=650) with <3 years from the first SSc symptom, including RP, were also analysed (31).

**7.2. Clinical phenotype**

7.2.1. Disease subset

The diffuse subset of the disease is more commonly observed in men compared to women (31). A cross-sectional study analysis which included 1,027 patients enrolled in the European Scleroderma Trials and Research group (EUSTAR) database, in patients with early disease (<3 years), men were more likely compared to women to have diffuse (61% vs. 34%) compared to limited (35% vs. 57%) cutaneous SSc (30).

7.22. Digital vasculopathy

In general, digital vasculopathy has been reported to be more severe in men, including digital ulcer (DU) disease (46,49–53). However, some investigators have either found no difference in DU disease between the sexes (54) or being more common in females (55). In the previously described Turkish study, DUs developed within the first three years in 54% of men compared to 31% of women (46). Although RP is more common in women (56), men report a lower median daily frequency of attacks of RP compared to women (0.82 vs. 1.93, respectively) (57). In a study which included 4,642 patients with complete information on their digital gangrene status, the odds ratio of females (compared to males) developing gangrene was 0.73 (95% CI = 0.53-1.01, P=0.055) during the observation period between April 2008 and November 2014 (58).

7.2.3. Cardiac

There is an emerging evidence to suggest that men may have a greater risk of scleroderma heart disease/cardiomyopathy (41,45,59–62). For example, in a prospective observational study which included 9,182 patients with at least two years follow-up data, extracted from the EUSTAR database, male sex was independently associated with heart failure (odds ratio of 2.22) (60). Furthermore, in another case-control study of patients (n=7,073) from the EUSTAR database, multiple regression revealed that male sex was independently associated (odds ratio of 3.48) with left ventricular dysfunction (59).

7.2.4. Respiratory

Respiratory involvement: pulmonary artery hypertension (PAH) and interstitial lung disease (ILD) are now the leading causes of disease-related mortality in patients with SSc. The extant literature strongly indicates that ILD is more common in men (41,45,63). For example, in the Spanish RESCLE study, male sex was independently associated with ILD (odds ratio of 1.58) (41). Male sex has also been reported to be associated with progression of ILD (64,65).

Previous studies have reported a preponderance of pulmonary hypertension in both males (45,60,63) and females (41,66). For example, in the previously described EUSTAR study examining cardiac dysfunction in SSc, male sex was independently predictive of new onset PAH (odds ratio of 2.66) (60). In a study that included patients with SSc-PAH enrolled in the DETECT cohort study for up to three years, univariate logistic regression revealed that male sex was associated (odds ratio of 4.1) with disease progression (67). Whereas, in the Spanish RESCLE cohort study, the investigators reported a clear predominance of pulmonary hypertension in females, in particular, in the absence of interstitial lung disease (41). Of mechanistic interest, Scorza et al (22) conducted a retrospective cohort study of female (n=189) patients with SSc and observed that the postmenopausal condition was significantly associated (odds ratio of 5.2) with the development of isolated PAH. The authors also found evidence of a significant association between the postmenopausal condition and HLA-B35 (odds ratio of 15.2) (22). Furthermore, in a small retrospective cohort study of 61 patients with SSc, in those 20 patients who received hormone replacement therapy (for a mean duration of 6.7 years), none of the patients developed isolated pulmonary hypertension, compared to 8 (out of 41) who did and were studied for a similar time period (68). Pasarikovski et al (69) reported significant sex disparities in their cohort study of 378 patients with SSc-PAH. Compared to female patients, males had a shorter time from SSc diagnosis to PAH diagnosis (1.7 vs. 5.5 years) and shorter PAH duration (3.5 vs. 4.7 years) (69).

7.2.5. Renal

Scleroderma renal crisis is a potentially life-threatening complication in SSc and is strongly associated with recent steroid exposure (70,71). Male sex has been reported to be associated with an increased risk of scleroderma renal crisis (41,46,69,72). For example, in the previously described study by Panopoulos et al, during the first three years from disease onset, the scleroderma renal crisis developed in 17% of men and 3% of women (46). Similarly, Pasarikovski et al (69) examined sex disparities in SSc, and observed an increased frequency of renal crisis in males compared to females (19% vs. 8%, respectively).

7.2.6. Gastrointestinal/genitourinary

There is no clear evidence for significant sex differences relating to gastrointestinal (GI) involvement in SSc (41,73). However, it is important to highlight that GI involvement is highly heterogeneous and often multifactorial within the SSc population. In an international multicentre study, which assessed urinary incontinence and quality of life of patients with SSc (n=334) as assessed by self-administered questionnaires, the prevalence of incontinence was 63%, and this was significantly associated with female sex (odds ratio of 10.8) (74).

7.2.7. Bone health

A higher prevalence of osteoporosis has been reported in patients with SSc compared to the general population. However, this remains a contested issue, including whether there is any difference observed between the sexes (75–78). In a recent cohort study using the Taiwan National Insurance database, compared to age- and sex matched controls, patients with SSc (n=1,712) had a significantly high incidence rate ratio of vertebral (1.78) and hip (1.89) fractures (79). Multivariable cox regression analysis revealed that female sex was a significant risk factor (hazard ratio of 4.88) for osteoporotic fractures (79).

**8.Mortality**

Men with SSc have been consistently reported worldwide to be have a higher rate of premature death than their female counterparts (41,45,66,80,81). In the previously described study from Detroit, male sex negatively affected survival (odds ratio of 1.81) (17). In another large single-center cohort study from Pittsburgh, which included 2,686 consecutive patients with SSc, males had significantly reduced survival at 5 and 10 years after the onset of SSc (73% and 45%, respectively) (45). Similarly, In a study from the United Kingdom, during a mean duration of follow-up of 12.5 years, the standardised mortality ratio was higher in men compared to women (1.54 vs. 1.30, respectively) (82). However, it is important to note that males have a higher death rate in the general population compared to females. Sex has been reported to be a very important (negative) determinant of SSc-PAH survival (83,84), including in the modern era (84). In a systematic review and meta-analysis, which included 22 studies, male sex was associated with a hazard ratio for survival of 1.57 (83).

**9. Transgender individuals**

Only one study that has considered SSc in transgender individuals was identified. Campochiaro et al (60) reported a case series of three patients who developed SSc after they had initiated hormonal therapy as part of their transition (male to female). The authors highlight in their cases (and another two additional cases from the literature) the very heterogeneous clinical and antibody profile of the patients, and the absence of any evidence-base to guide the continuation or cessation of hormonal therapies. In their detailed review of the literature, they highlight the different mechanisms by which hormonal modification, as part of gender transition, could be relevant in the acquired development of SSc (60).

**10. Psychosocial aspects**

Five papers were identified that focused on psychosocial aspects of SSc. All were quantitative and had insufficient male participants in their study samples to enable definitive conclusions on sex differences to be drawn. No qualitative studies were identified that have considered the influence of gender (i.e. the socially constructed characteristics of women and men, rather than biological ones) on issues such as work disability; psychosocial impact of sexual functioning, intimacy and relationships; nor self-management and coping.

Two studies have considered sex differences in health-related quality of life (HRQoL). A French cross-sectional study found both male and female SSc patients (n=379; 16% male) to have mean scores lower than 40 out of 100 on all eight domains of the SF-36 including both physical and mental components (63). This indicates poor HRQoL when compared with normative SF-36 scores, which have been reported to range from 60.3-88.4 (85). A Chinese cross-sectional study (86) reported there were no sex differences between SF-36 scores for patients with SSc. However, they did disaggregate and report male and female data, and only 13% (10/38) of the sample were male.

Nguyen et al (63,87) have found anxiety slightly more common in female than male SSc patients (62.3% vs 43.5%) as measured by the Hospital Anxiety and Depression Scale (HADS) (88). However, this finding did not reach statistical significance, and male and female patients did not differ according to levels of depression. A Serbian cross-sectional study (89) (n=35, 23% male) did not contain sufficient male patients to statistically compare gender differences, but reported 78% of female patients experienced depression compared to 38% of male patients (three of eight men) according to the Beck Depression Inventory (90), whilst 78% of female patients experienced anxiety compared to 88% of male patients (seven of eight men) according to the Zung’s anxiety self-assessment scale (91).

One study (92) has focused on body image with participants (n=98; 12% male) completing Likert scales to rate body image dissatisfaction relating to typical features of SSc such as finger ulcers and hand contractures. The authors noted high levels of body image dissatisfaction in both men and women, but did not include sufficient male patients to compare sex differences.

**11. Conclusion**

This review has drawn together the current evidence on sex differences in SSc for the first time. Although SSc is less common in men compared to women, men have a more severe expression of the disease including internal organ-based complications and higher mortality. The higher death male death rate in the general population is probably the most important factor responsible for excess mortality together with a greater prevalence of lung fibrosis. The extant literature shows that although pathophysiological sex differences are present in SSc, behavioural differences (e.g. higher smoking rates in men) and occupational exposures may contribute to poorer outcomes in men with SSc. Other important factors include (but are not limited to) a greater prevalence of the disease subset, delayed time to diagnosis, and higher disease activity in early disease in men. SSc carries a significant burden of disease-related morbidity; however, to date, no qualitative studies to date have focussed on gender differences in SSc. Future research is required to understand gender differences in SSc including to understand the experiences and support preferences of men to inform clinical practice and contribute to the development of appropriate and effective care tailored to men with SSc.

**References**

1. Denton CP, Khanna DK. Systemic sclerosis. Lancet. 2017;390(10103):1685–99.

2. Hughes M, Herrick AL. Systemic sclerosis. Br J Hosp Med. 2019;80(9):530–6.

3. Henry TW, Mendoza FA, Jimenez SA. Role of microRNA in the pathogenesis of systemic sclerosis tissue fibrosis and vasculopathy. Autoimmun Rev [Internet]. 2019;18(11):102396. Available from: http://www.sciencedirect.com/science/article/pii/S1568997219302034

4. Medsger Jr. TA, Masi A. Epidemiology of Systemic Sclerosis (Scleroderma). Ann Intern Med [Internet]. 1971 May 1;74(5):714–21. Available from: https://doi.org/10.7326/0003-4819-74-5-714

5. Michet Jr C, McKenna C, Elveback L, Kaslow R, Kurland L. Epidemiology of Systemic Lupus Erythematosus and Other Connective Tissue Diseases in Rochester, Minnesota, 1950 Through 1979. Mayo Clin Proc [Internet]. 1985;60(2):105–13. Available from: http://www.sciencedirect.com/science/article/pii/S0025619612602948

6. Silman A. Epidemiology of scleroderma. Curr Opin Rheumatol. 1991;3:967-72.

7. Geirsson AJ, Steinsson K, Guthmundsson S, Sigurthsson V. Systemic sclerosis in Iceland. A nationwide epidemiological study. Ann Rheum Dis [Internet]. 1994 Aug;53(8):502–5. Available from: https://www.ncbi.nlm.nih.gov/pubmed/7944633

8. Chandran G, Ahern MJ, Smith M, Roberts-Thomson PJ. A study of scleroderma in South Australia: prevalence, subset characteristics and nailfold capillaroscopy. Aust N Z J Med [Internet]. 1995 Dec 1;25(6):688–94. Available from: https://doi.org/10.1111/j.1445-5994.1995.tb02854.x

9. Arnett FC, Howard RF, Tan F, Moulds JM, Bias WB, Durban E, et al. Increased prevalence of systemic sclerosis in a native american tribe in oklahoma. Association with an amerindian HLA haplotype. Arthritis Rheum [Internet]. 1996 Aug 1;39(8):1362–70. Available from: https://doi.org/10.1002/art.1780390814

10. Englert H, Small-McMahon J, Davis K, O’Connor H, Chambers P, Brooks P. Systemic sclerosis prevalence and mortality in Sydney 1974-88. Aust N Z J Med [Internet]. 1999 Feb 1;29(1):42–50. Available from: https://doi.org/10.1111/j.1445-5994.1999.tb01587.x

11. Mayes M. Scleroderma epidemiology. Rheum Dis Clin North Am. 2006;22(4):751-64.

12. Abbot S, Bossingham D, Proudman S, de Costa C, Ho-Huynh A. Risk factors for the development of systemic sclerosis: a systematic review of the literature. Rheumatol Adv Pract [Internet]. 2018 Oct 11;2(2). Available from: https://doi.org/10.1093/rap/rky041

13. Tamaki T, Mori S, Takehara K. Epidemiological study of patients with systemic sclerosis in Tokyo. Arch Dermatol Res [Internet]. 1991;283(6):366–71. Available from: https://doi.org/10.1007/BF00371817

14. Silman A, Jannini S, Symmons D, Bacon P. AN EPIDEMIOLOGICAL STUDY OF SCLERODERMA IN THE WEST MIDLANDS. Rheumatology [Internet]. 1988 Aug 1;27(4):286–90. Available from: https://doi.org/10.1093/rheumatology/27.4.286

15. Allcock RJ, Forrest I, Corris PA, Crook PR, Griffiths ID. A study of the prevalence of systemic sclerosis in northeast England. Rheumatology (Oxford) [Internet]. 2004 May [cited 2016 Jun 20];43(5):596–602. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14872101

16. Royle JG, Lanyon PC, Grainge MJ, Abhishek A, Pearce FA. The incidence, prevalence, and survival of systemic sclerosis in the UK Clinical Practice Research Datalink. Clin Rheumatol [Internet]. 2018;37(8):2103–11. Available from: https://doi.org/10.1007/s10067-018-4182-3

17. Mayes MD, Lacey J V, Beebe-Dimmer J, Gillespie BW, Cooper B, Laing TJ, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum [Internet]. 2003 Aug [cited 2016 Jun 20];48(8):2246–55. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12905479

18. Gelber AC, Manno RL, Shah AA, Woods A, Le EN, Boin F, et al. Race and association with disease manifestations and mortality in scleroderma: a 20-year experience at the Johns Hopkins Scleroderma Center and review of the literature. Medicine (Baltimore) [Internet]. 2013 Jul [cited 2016 Jun 20];92(4):191–205. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23793108

19. Nietert PJ, Silver RM. Patterns of hospital admissions and emergency room visits among patients with scleroderma in South Carolina, USA. J Rheumatol [Internet]. 2003 Jun 1;30(6):1238 LP – 1243. Available from: http://www.jrheum.org/content/30/6/1238.abstract

20. D’Amico F, Skarmoutsou E, Mazzarino MC. The Sex Bias in Systemic Sclerosis: on the Possible Mechanisms Underlying the Female Disease Preponderance. Clin Rev Allergy Immunol [Internet]. 2014;47(3):334–43. Available from: https://doi.org/10.1007/s12016-013-8392-9

21. Ciaffi J, van Leeuwen NM, Schoones JW, Huizinga TWJ, de Vries-Bouwstra JK. Sex hormones and sex hormone-targeting therapies in systemic sclerosis: A systematic literature review. Semin Arthritis Rheum [Internet]. 2019; Available from: http://www.sciencedirect.com/science/article/pii/S0049017219302987

22. Scorza R, Caronni M, Bazzi S, Nador F, L B, Antoniolli R, et al. Post-Menopause is the Main Risk Factor for Developing Isolated Pulmonary Hypertension in Systemic Sclerosis. Ann N Y Acad Sci [Internet]. 2002 Jun 1;966(1):238–46. Available from: https://doi.org/10.1111/j.1749-6632.2002.tb04221.x

23. Vinet É, Bernatsky S, Hudson M, Pineau CA, Baron M, Group the CSR. Effect of menopause on the modified Rodnan skin score in systemic sclerosis. Arthritis Res Ther [Internet]. 2014;16(3):R130. Available from: https://doi.org/10.1186/ar4587

24. Avouac J, Pezet S, Gonzalez V, Baudoin L, Cauvet A, Ruiz B, et al. Estrogens counteract the profibrotic effects of TGFGF-β and their inhibition exacerbates experimental dermal fibrosis. J Invest Dermatol [Internet]. 2019 Sep 25; Available from: https://doi.org/10.1016/j.jid.2019.07.719

25. Baker Frost D, Wolf B, Peoples C, Fike J, Silver K, Laffoon M, et al. Estradiol levels are elevated in older men with diffuse cutaneous SSc and are associated with decreased survival. Arthritis Res Ther [Internet]. 2019 Apr 2;21(1):85. Available from: https://www.ncbi.nlm.nih.gov/pubmed/30940202

26. Perković D, Martinović Kaliterna D, Jurišić Z, Lalovac M, Radić M. Androgens in post-menopausal patients with systemic sclerosis. Rheumatology [Internet]. 2014 Dec 17;54(4):744–6. Available from: https://doi.org/10.1093/rheumatology/keu432

27. Seminog OO, Seminog AB, Yeates D, Goldacre MJ. Associations between Klinefelter’s syndrome and autoimmune diseases: English national record linkage studies. Autoimmunity [Internet]. 2015 Feb 17;48(2):125–8. Available from: https://doi.org/10.3109/08916934.2014.968918

28. Selmi C, Feghali-Bostwick CA, Lleo A, Lombardi SA, De Santis M, Cavaciocchi F, et al. X chromosome gene methylation in peripheral lymphocytes from monozygotic twins discordant for scleroderma. Clin Exp Immunol [Internet]. 2012 Sep;169(3):253–62. Available from: https://www.ncbi.nlm.nih.gov/pubmed/22861365

29. Broen JCA, Wolvers-Tettero ILM, Geurts-van Bon L, Vonk MC, Coenen MJH, Lafyatis R, et al. Skewed X chromosomal inactivation impacts T regulatory cell function in systemic sclerosis. Ann Rheum Dis [Internet]. 2010 Dec 1;69(12):2213 LP – 2216. Available from: http://ard.bmj.com/content/69/12/2213.abstract

30. Dieudé P, Bouaziz M, Guedj M, Riemekasten G, Airò P, Müller M, et al. Evidence of the contribution of the X chromosome to systemic sclerosis susceptibility: Association with the functional IRAK1 196Phe/532Ser haplotype. Arthritis Rheum [Internet]. 2011 Dec 1;63(12):3979–87. Available from: https://doi.org/10.1002/art.30640

31. Carreira PE, Carmona L, Joven BE, Loza E, Andreu J, Riemekasten G, et al. Gender differences in early systemic sclerosis patients: a report from the EULAR scleroderma trials and research group (EUSTAR) database. Clin Exp Rheumatol. 2018;36 Suppl 1(4):68–75.

32. Carmona FD, Cénit MC, Diaz-Gallo L-M, Broen JCA, Simeón CP, Carreira PE, et al. New insight on the Xq28 association with systemic sclerosis. Ann Rheum Dis [Internet]. 2013 Dec 1;72(12):2032 LP – 2038. Available from: http://ard.bmj.com/content/72/12/2032.abstract

33. Vreca M, Andjelkovic M, Tosic N, Zekovic A, Damjanov N, Pavlovic S, et al. Impact of alterations in X-linked IRAK1gene and miR-146a on susceptibility and clinical manifestations in patients with systemic sclerosis. Immunol Lett [Internet]. 2018;204:1–8. Available from: http://www.sciencedirect.com/science/article/pii/S0165247818302992

34. Granel B, Allanore Y, Chevillard C, Arnaud V, Marquet S, Weiller P-J, et al. IL13RA2 gene polymorphisms are associated with systemic sclerosis. J Rheumatol [Internet]. 2006 Oct 1;33(10):2015 LP – 2019. Available from: http://www.jrheum.org/content/33/10/2015.abstract

35. Liang Y, Tsoi LC, Xing X, Beamer MA, Swindell WR, Sarkar MK, et al. A gene network regulated by the transcription factor VGLL3 as a promoter of sex-biased autoimmune diseases. Nat Immunol [Internet]. 2016 Dec 19;18:152. Available from: https://doi.org/10.1038/ni.3643

36. Launay D, Hebbar M, Hatron PY, Michon-Pasturel U, Queyrel V, Hachulla E, et al. Relationship between parity and clinical and biological features in patients with systemic sclerosis. J Rheumatol [Internet]. 2001 Mar 1;28(3):509 LP – 513. Available from: http://www.jrheum.org/content/28/3/509.abstract

37. Steen VD, Powell DL, Medsger Jr. TA. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum [Internet]. 1988 Feb 1;31(2):196–203. Available from: https://doi.org/10.1002/art.1780310207

38. Steen VD. Autoantibodies in Systemic Sclerosis. Semin Arthritis Rheum [Internet]. 2005 Aug [cited 2018 Mar 28];35(1):35–42. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16084222

39. Krzyszczak ME, Li Y, Ross SJ, Ceribelli A, Chan EKL, Bubb MR, et al. Gender and ethnicity differences in the prevalence of scleroderma-related autoantibodies. Clin Rheumatol [Internet]. 2011/04/27. 2011 Oct;30(10):1333–9. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21523365

40. Motegi S, Toki S, Yamada K, Uchiyama A, Ishikawa O. Demographic and clinical features of systemic sclerosis patients with anti-RNA polymerase III antibodies. J Dermatol [Internet]. 2015 Feb 1;42(2):189–92. Available from: https://doi.org/10.1111/1346-8138.12722

41. Freire M, Rivera A, Sopeña B, Tolosa Vilella C, Guillén-Del Castillo A, Colunga Argüelles D, et al. Clinical and epidemiological differences between men and women with systemic sclerosis: a study in a Spanish systemic sclerosis cohort and literature review. Clin Exp Rheumatol [Internet]. [cited 2018 Jan 18];35 Suppl 106(4):89–97. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28980905

42. Salazar GA, Assassi S, Wigley F, Hummers L, Varga J, Hinchcliff M, et al. Antinuclear antibody-negative systemic sclerosis. Semin Arthritis Rheum [Internet]. 2014/11/28. 2015 Jun;44(6):680–6. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25578738

43. Delisle VC, Hudson M, Baron M, Thombs BD, And The Canadian Scleroderma Research Group A. Sex and time to diagnosis in systemic sclerosis: an updated analysis of 1,129 patients from the Canadian scleroderma research group registry. Clin Exp Rheumatol [Internet]. [cited 2019 Feb 28];32(6 Suppl 86):S-10-4. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24144459

44. Hudson M, Thombs B, Baron M, Group TCSR. Time to diagnosis in systemic sclerosis: Is sex a factor? Arthritis Care Res (Hoboken) [Internet]. 2009 Feb 15;61(2):274–8. Available from: https://doi.org/10.1002/art.24284

45. Peoples C, Medsger TA, Lucas M, Rosario BL, Feghali-Bostwick CA. Gender differences in systemic sclerosis: relationship to clinical features, serologic status and outcomes. J Scleroderma Relat Disord [Internet]. 2016 May 1;1(2):204–12. Available from: https://doi.org/10.5301/jsrd.5000209

46. Panopoulos ST, Bournia V-K, Sfikakis PP. Is vasculopathy associated with systemic sclerosis more severe in men? J Rheumatol [Internet]. 2013 Jan [cited 2015 Sep 10];40(1):46–51. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23118107

47. Marie I. Systemic sclerosis and exposure to heavy metals. Autoimmun Rev [Internet]. 2019;18(1):62–72. Available from: http://www.sciencedirect.com/science/article/pii/S1568997218302623

48. Marie I, Gehanno J-F, Bubenheim M, Duval-Modeste A-B, Joly P, Dominique S, et al. Systemic sclerosis and exposure to heavy metals: A case control study of 100 patients and 300 controls. Autoimmun Rev [Internet]. 2017;16(3):223–30. Available from: http://www.sciencedirect.com/science/article/pii/S1568997217300149

49. Tiev KP, Diot E, Clerson P, Dupuis-Siméon F, Hachulla E, Hatron PY, et al. Clinical features of scleroderma patients with or without prior or current ischemic digital ulcers: Post-hoc analysis of a nationwide multicenter cohort (ItinérAIR-Sclérodermie). J Rheumatol. 2009;36(7):1470–6.

50. Manfredi A, Sebastiani M, Carraro V, Iudici M, Bocci M, Vukatana G, et al. Prediction risk chart for scleroderma digital ulcers: a composite predictive model based on capillaroscopic, demographic and clinico-serological parameters. Clin Hemorheol Microcirc [Internet]. 2015 Jan [cited 2015 Sep 10];59(2):133–43. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24464851

51. Sebastiani M, Manfredi A, Colaci M, D’amico R, Malagoli V, Giuggioli D, et al. Capillaroscopic skin ulcer risk index: a new prognostic tool for digital skin ulcer development in systemic sclerosis patients. Arthritis Rheum [Internet]. 2009 May 15 [cited 2015 Aug 6];61(5):688–94. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19405007

52. Mecoli CA, Shah AA, Boin F, Wigley FM, Hummers LK. Vascular complications in systemic sclerosis: a prospective cohort study. Clin Rheumatol [Internet]. 2018;37(9):2429–37. Available from: https://doi.org/10.1007/s10067-018-4148-5

53. Hughes M, Herrick AL. Digital ulcers in systemic sclerosis. Rheumatology [Internet]. 2017 Jan [cited 2017 May 1];56(1):14–25. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27094599

54. Khimdas S, Harding S, Bonner A, Zummer B, Baron M, Pope J. Associations with digital ulcers in a large cohort of systemic sclerosis: Results from the canadian scleroderma research group registry. Arthritis Care Res. 2011;63(1):142–9.

55. Xu D, Li M-T, Hou Y, Wang Q, Hu C-J, Song N, et al. Clinical characteristics of systemic sclerosis patients with digital ulcers in China. Clin Exp Rheumatol [Internet]. 2015 Jan [cited 2015 Aug 3];31(2 Suppl 76):46–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23910609

56. Hughes M, Herrick AL. Raynaud’s phenomenon. Best Pract Res Clin Rheumatol. 2016;30(1).

57. Pauling JD, Shipley JA, Hart DJ, McGrogan A, McHugh NJ. Use of Laser Speckle Contrast Imaging to Assess Digital Microvascular Function in Primary Raynaud Phenomenon and Systemic Sclerosis: A Comparison Using the Raynaud Condition Score Diary. J Rheumatol [Internet]. 2015 Jul [cited 2019 Feb 28];42(7):1163–8. Available from: http://www.jrheum.org/lookup/doi/10.3899/jrheum.141437

58. Allanore Y, Denton CP, Krieg T, Cornelisse P, Rosenberg D, Schwierin B, et al. Clinical characteristics and predictors of gangrene in patients with systemic sclerosis and digital ulcers in the Digital Ulcer Outcome Registry: a prospective, observational cohort. Ann Rheum Dis [Internet]. 2016 Sep 1;75(9):1736 LP – 1740. Available from: http://ard.bmj.com/content/75/9/1736.abstract

59. Allanore Y, Meune C, Vonk MC, Airo P, Hachulla E, Caramaschi P, et al. Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis. Ann Rheum Dis [Internet]. 2010 Jan 1;69(01):218 LP – 221. Available from: http://ard.bmj.com/content/69/01/218.abstract

60. Elhai M, Avouac J, Walker UA, Matucci-Cerinic M, Riemekasten G, Airò P, et al. A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study. Ann Rheum Dis [Internet]. 2016 Jan [cited 2016 Jun 20];75(1):163–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25342760

61. Sanz Pérez I, Martínez Valle F, Guillén-del-Castillo A, Roque Pérez A, Cuéllar Calàbria H, Pizzi MN, et al. Subclinical cardiovascular disease and Systemic Sclerosis: A comparison between risk charts, quantification of coronary calcium and carotid ultrasonography. Autoimmun Rev [Internet]. 2018;17(9):900–5. Available from: http://www.sciencedirect.com/science/article/pii/S1568997218301605

62. Zanatta E, Famoso G, Boscain F, Montisci R, Pigatto E, Polito P, et al. Nailfold avascular score and coronary microvascular dysfunction in systemic sclerosis: A newsworthy association. Autoimmun Rev [Internet]. 2019;18(2):177–83. Available from: http://www.sciencedirect.com/science/article/pii/S156899721830288X

63. Nguyen C, Bérezné A, Baubet T, Mestre-Stanislas C, Rannou F, Papelard A, et al. Association of gender with clinical expression, quality of life, disability, and depression and anxiety in patients with systemic sclerosis. PLoS One [Internet]. 2011 Mar 9;6(3):e17551–e17551. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21408076

64. Winstone TA, Assayag D, Wilcox PG, Dunne J V, Hague CJ, Leipsic J, et al. Predictors of Mortality and Progression in Scleroderma-Associated Interstitial Lung Disease: A Systematic Review. Chest [Internet]. 2014 Aug 1;146(2):422–36. Available from: https://doi.org/10.1378/chest.13-2626

65. Moll M, Christmann RB, Zhang Y, Whitfield ML, Wang YM, Rice L, et al. Patients with systemic sclerosis-associated pulmonary arterial hypertension express a genomic signature distinct from patients with interstitial lung disease. J Scleroderma Relat Disord [Internet]. 2018 Mar 22;3(3):242–8. Available from: https://doi.org/10.1177/2397198318764780

66. Hussein H, Lee P, Chau C, Johnson SR. The effect of male sex on survival in systemic sclerosis. J Rheumatol [Internet]. 2014 Nov [cited 2016 Jun 20];41(11):2193–200. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25274896

67. Mihai C, Antic M, Dobrota R, Bonderman D, Chadha-Boreham H, Coghlan JG, et al. Factors associated with disease progression in early-diagnosed pulmonary arterial hypertension associated with systemic sclerosis: longitudinal data from the DETECT cohort. Ann Rheum Dis [Internet]. 2018 Jan 1;77(1):128 LP – 132. Available from: http://ard.bmj.com/content/77/1/128.abstract

68. Beretta L, Caronni M, Origgi A, Ponti A, Santaniello A, Scorza R. Hormone replacement therapy may prevent the development of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Scand J Rheumatol. 2006;35(6):468–71.

69. Pasarikovski CR, Granton JT, Roos AM, Sadeghi S, Kron AT, Thenganatt J, et al. Sex disparities in systemic sclerosis-associated pulmonary arterial hypertension: a cohort study. Arthritis Res Ther [Internet]. 2016 Jan 27;18:30. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26819137

70. Zanatta E, Polito P, Favaro M, Larosa M, Marson P, Cozzi F, et al. Therapy of scleroderma renal crisis: State of the art. Autoimmun Rev [Internet]. 2018;17(9):882–9. Available from: http://www.sciencedirect.com/science/article/pii/S1568997218301575

71. Blagojevic J, Legendre P, Matucci-Cerinic M, Mouthon L. Is there today a place for corticosteroids in the treatment of scleroderma? Autoimmun Rev [Internet]. 2019;102403. Available from: http://www.sciencedirect.com/science/article/pii/S1568997219302101

72. Jaeger VK, Wirz EG, Allanore Y, Rossbach P, Riemekasten G, Hachulla E, et al. Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study. PLoS One [Internet]. 2016 Oct 5;11(10):e0163894–e0163894. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27706206

73. Karamanolis G, Denaxas K, Panopoulos ST, Bournia K, Zorbala A, Kamberoglou D, et al. Severe oesophageal disease and its associations with systemic sclerosis. Clin Exp Rheumatol. 2017;35 Suppl 1(4):82–5.

74. John G, Allanore Y, Polito P, Piantoni S, Fredi M, Avouac J, et al. The limited cutaneous form of systemic sclerosis is associated with urinary incontinence: an international multicentre study. Rheumatology [Internet]. 2017 Aug 1;56(11):1874–83. Available from: https://doi.org/10.1093/rheumatology/kex230

75. Loucks J, Pope JE. Osteoporosis in scleroderma. Semin Arthritis Rheum [Internet]. 2005;34(4):678–82. Available from: http://www.sciencedirect.com/science/article/pii/S0049017204001829

76. YUEN SAIYAN, ROCHWERG B, OUIMET J, POPE JE. Patients with Scleroderma May Have Increased Risk of Osteoporosis. A Comparison to Rheumatoid Arthritis and Noninflammatory Musculoskeletal Conditions. J Rheumatol [Internet]. 2008 Jun 1;35(6):1073 LP – 1078. Available from: http://www.jrheum.org/content/35/6/1073.abstract

77. Mok CC, Chan PT, Chan KL, Ma KM. Prevalence and risk factors of low bone mineral density in Chinese patients with systemic sclerosis: a case–control study. Rheumatology [Internet]. 2012 Sep 23;52(2):296–303. Available from: https://doi.org/10.1093/rheumatology/kes240

78. Marot M, Valéry A, Esteve E, Bens G, Müller A, Rist S, et al. Prevalence and predictive factors of osteoporosis in systemic sclerosis patients: a case-control study. Oncotarget [Internet]. 2015 Apr 12;6(17):14865–73. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25944694

79. Lai C-C, Wang S-H, Chen W-S, Liu C-J, Chen T-J, Lee P-C, et al. Increased risk of osteoporotic fractures in patients with systemic sclerosis: a nationwide population-based study. Ann Rheum Dis [Internet]. 2015 Jul 1;74(7):1347 LP – 1352. Available from: http://ard.bmj.com/content/74/7/1347.abstract

80. Hoffmann-Vold A-M, Molberg Ø, Midtvedt Ø, Garen T, Gran JT. Survival and Causes of Death in an Unselected and Complete Cohort of Norwegian Patients with Systemic Sclerosis. J Rheumatol [Internet]. 2013 Jul 1;40(7):1127 LP – 1133. Available from: http://www.jrheum.org/content/40/7/1127.abstract

81. Panopoulos S, Bournia V-K, Konstantonis G, Fragiadaki K, Sfikakis PP, Tektonidou MG. Predictors of morbidity and mortality in early systemic sclerosis: Long-term follow-up data from a single-centre inception cohort. Autoimmun Rev [Internet]. 2018;17(8):816–20. Available from: http://www.sciencedirect.com/science/article/pii/S1568997218301307

82. Strickland G, Pauling J, Cavill C, Shaddick G, McHugh N. Mortality in systemic sclerosis—a single centre study from the UK. Clin Rheumatol [Internet]. 2013;32(10):1533–9. Available from: https://doi.org/10.1007/s10067-013-2289-0

83. Lefèvre G, Dauchet L, Hachulla E, Montani D, Sobanski V, Lambert M, et al. Survival and Prognostic Factors in Systemic Sclerosis–Associated Pulmonary Hypertension: A Systematic Review and Meta-Analysis. Arthritis Rheum [Internet]. 2013 Sep 1;65(9):2412–23. Available from: https://doi.org/10.1002/art.38029

84. Launay D, Sitbon O, Hachulla E, Mouthon L, Gressin V, Rottat L, et al. Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era. Ann Rheum Dis [Internet]. 2013 Dec 1;72(12):1940 LP – 1946. Available from: http://ard.bmj.com/content/72/12/1940.abstract

85. Burholt V, Nash P. Short Form 36 (SF-36) Health Survey Questionnaire: normative data for Wales. J Public Health (Bangkok) [Internet]. 2011 Feb 9;33(4):587–603. Available from: https://doi.org/10.1093/pubmed/fdr006

86. Chan PT, Mok CC, Chan KL, Ho LY. Functioning and health-related quality of life in Chinese patients with systemic sclerosis: a case–control study. Clin Rheumatol [Internet]. 2014;33(5):659–66. Available from: https://doi.org/10.1007/s10067-014-2525-2

87. Nguyen C, Ranque B, Baubet T, Bérezné A, Mestre-Stanislas C, Rannou F, et al. Clinical, functional and health-related quality of life correlates of clinically significant symptoms of anxiety and depression in patients with systemic sclerosis: a cross-sectional survey. PLoS One [Internet]. 2014 Feb 28;9(2):e90484–e90484. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24587375

88. Stern AF. The Hospital Anxiety and Depression Scale. Occup Med (Chic Ill) [Internet]. 2014 Jun 28;64(5):393–4. Available from: https://doi.org/10.1093/occmed/kqu024

89. Ostojic P, Zivojinovic S, Reza T, Damjanov N. Symptoms of depression and anxiety in Serbian patients with systemic sclerosis: impact of disease severity and socioeconomic factors. Mod Rheumatol [Internet]. 2010;20(4):353–7. Available from: https://doi.org/10.1007/s10165-010-0285-7

90. Beck A, Steer R. BDI, Beck depression inventory: manual. New York: Psychological Corporation; 1987.

91. Zung WWK. A Rating Instrument For Anxiety Disorders. Psychosomatics [Internet]. 1971;12(6):371–9. Available from: http://www.sciencedirect.com/science/article/pii/S0033318271714790

92. Nusbaum JS, Gordon JK, Steen VD. African American race associated with body image dissatisfaction among patients with systemic sclerosis. Clin Exp Rheumatol [Internet]. [cited 2018 May 28];34 Suppl 100(5):70–3. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27192123